The effect of oral micronized progesterone on hormonal and metabolic parameters in anovulatory patients with polycystic ovary syndrome

Fertility and Sterility

Volumn 94, Issue 1, 2010, Pages 242-246

  Livadas, Sarantis ^a   Boutzios, Georgios ^a   Economou, Fragiskos ^a   Alexandraki, Krystallenia ^a   Xyrafis, Xenofon ^a   Christou, Maria ^a   Zerva, Aristea ^a   Karachalios, Athanasios ^a   Tantalaki, Evangelia ^a   Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Androgens; HOMA IR; hyperandrogenism; polycystic ovary syndrome; progesterone

Indexed keywords

ANDROGEN; FOLLITROPIN; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANOVULATION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE DETERMINATION; HUMAN; INSULIN SENSITIVITY; METABOLIC PARAMETERS; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TREATMENT DURATION; WITHDRAWAL BLEEDING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANOVULATION; FEMALE; HUMANS; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; PROGESTERONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952551458     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.02.073     Document Type: Article

References (20)

1. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
2. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 10 (2008) e3
3. Shangold M.M., Tomai T.P., Cook J.D., Jacobs S.L., Zinaman M.J., Chin S.Y., et al. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril 56 (1991) 1040-1047
4. Unfer V., Casini M.L., Marelli G., Costabile L., Gerli S., and Di Renzo J.C. Different routes of progesterone administration and polycystic ovary syndrome: a review of the literature. Gynecol Endocrinol 21 (2005) 119-127
5. Bagis T., Gokcel A., Zeyneloglu H.B., Tarim E., Kilicdag E.B., and Haydardedeoglu B. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab 87 (2002) 4536-4540
6. Woods K.S., Reyna R., and Azziz R. Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. Fertil Steril 77 (2002) 1125-1127
7. Zawadski J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In: Dunaif A., Givens J.R., Haseltine F.P., and Merriam G.R. (Eds). Polycystic ovary syndrome (1992), Blackwell Scientific Publications, Boston 377-384
8. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.I. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
9. Anttila L., Koskinen P., Erkkola R., Irjala K., and Ruutiainen K. Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Acta Obstet Gynecol Scand 73 (1994) 634-636
10. Anttila L., Koskinen P., Kaihola H.L., Erkkola R., Irjala K., and Ruutiainen K. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries. Fertil Steril 58 (1992) 697-702
11. Fiad T.M., Cunningham S.K., and McKenna T.J. Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. Eur J Endocrinol 135 (1996) 335-339
12. McAuley J.W., Kroboth F.J., and Froboth P.D. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy 16 (1996) 453-457
13. Maxson W.S., and Hargrove J.T. Bioavailability of oral micronized progesterone. Fertil Steril 44 (1985) 622-626
14. Hargrove J.T., Maxson W.S., and Wentz A.C. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 161 (1989) 948-951
15. Ottosson U.B., Carlstrom K., Damber J.E., and von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol 91 (1984) 1111-1119
16. de Lignières B. Oral micronized progesterone. Clin Therapeutics 21 (1999) 41-60
17. Martens J.W.M., Geller D.H., Arlt W., Auchus R.J., Ossovskaya V.S., Rodriguez H., et al. Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome. J Clin Endocrinol Metab 85 (2000) 4338-4346
18. Writing Group for the PEP1 Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273 (1995) 199-208
19. Wagner J.D., Martin M.A., Jayo M.J., Anthony M.S., Clarkson T.B., and Cefalu W.T. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal Cynomolgus monkeys. Metabolism 45 (1996) 1254-1262
20. Elkind-Hirsch K.E., Sherman L.D., and Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 76 (1993) 472-475